152 related articles for article (PubMed ID: 37290395)
1. Combined expression of HIF1α, VEGF and HER2 predicts metastasis, relapse and response to combination chemotherapy in colorectal cancer patients.
Jamai D; Kallel I; Mekrazi S; Aloulou S; Walha M; Selmi B; Khabir A
Ann Diagn Pathol; 2023 Oct; 66():152168. PubMed ID: 37290395
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
Oh SY; Kwon HC; Kim SH; Lee S; Lee JH; Graves CA; Camphausen K; Kim HJ
Chemotherapy; 2012; 58(6):426-34. PubMed ID: 23295255
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
4. VEGF -460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma.
Chen MH; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Pharmacogenomics J; 2011 Jun; 11(3):227-36. PubMed ID: 20531372
[TBL] [Abstract][Full Text] [Related]
5. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
[TBL] [Abstract][Full Text] [Related]
6. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
7. Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab.
Berk V; Deniz K; Bozkurt O; Ozaslan E; Karaca H; Inanc M; Duran AO; Ozkan M
Asian Pac J Cancer Prev; 2015; 16(14):6149-54. PubMed ID: 26320510
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Okita NT; Yamada Y; Takahari D; Hirashima Y; Matsubara J; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
Jpn J Clin Oncol; 2009 Sep; 39(9):595-600. PubMed ID: 19535387
[TBL] [Abstract][Full Text] [Related]
10. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
11. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
[TBL] [Abstract][Full Text] [Related]
12. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
[TBL] [Abstract][Full Text] [Related]
13. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G
Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280
[TBL] [Abstract][Full Text] [Related]
14. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
J Clin Oncol; 2006 Sep; 24(26):4301-8. PubMed ID: 16896001
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia.
Jamai D; Gargouri R; Selmi B; Khabir A
Genes (Basel); 2023 Jul; 14(7):. PubMed ID: 37510370
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
[TBL] [Abstract][Full Text] [Related]
17. Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Konishi T; Horie H; Ikeuchi H; Eshima K; Muto T
Clin Transl Oncol; 2011 Jun; 13(6):419-25. PubMed ID: 21680303
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study.
Badary DM; Elkabsh MM; Mady HH; Gabr A; Kroosh SS
Appl Immunohistochem Mol Morphol; 2020; 28(10):741-747. PubMed ID: 32118594
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
Feng QY; Wei Y; Chen JW; Chang WJ; Ye LC; Zhu DX; Xu JM
World J Gastroenterol; 2014 Apr; 20(15):4263-75. PubMed ID: 24764664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]